Loading stock data…
Bayer AG N (BAYN.DE)
€48.41+2.38 (+5.17%)
Market ClosedLast close Jun 30
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bayer Aktiengesellschaft in the Healthcare sector is trading at €48.41 with a market capitalization of $35.3B. Wall Street consensus targets €51.64 (18 analysts), implying a +6.7% move over the next 12 months. The stock is currently near its 52-week high of €49.78, remaining 34.1% above its 200-day moving average. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (EUR) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | €13.74B↑ | €10.74B↑ | €9.66B↓ | €11.44B↓ | €13.40B |
| Gross Profit | €8.11B↑ | €6.38B↑ | €5.35B↓ | €6.94B↓ | €8.17B |
| Operating Income | €2.32B↑ | €13.00M↑ | -€543.00M↓ | €4.34B↑ | €3.53B |
| Net Income | €1.30B↑ | -€199.00M↑ | -€963.00M↑ | -€3.76B↓ | €2.76B |
Peer Comparison
JNJUNHPFE
Fundamentals
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€35.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Strong income play. Yield provides a meaningful total return floor.
31.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.93%
Volume
Today's trading volume
5.44M
Recent News
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Marjorie Taylor Greene Says It Is 'Awful' That 'No One Is Standing Up For Cancer Patients' After Bayer Scores Roundup Victory In Supreme Court
Former Rep. Marjorie Taylor Greene criticized both the U.S. Supreme Court and President Donald Trump after the court sided with Bayer AG in a major Roundup lawsuit, saying “no one is standing up for cancer patients.” Greene Slams Supreme Court,...
Health Care Roundup: Market Talk
0520 ET – Bayer scored a big win in the U.S. Supreme Court with a ruling in its favor in a case over its Roundup weedkiller, which means investors’ focus can shift elsewhere, Bank of America says. A proposed U.S. class settlement for Roundup litigation, the launch of stroke-prevention drug asundexian and Bayer’s efforts to reduce debt should be next on investors’ watchlists, according to Bank of America. The Roundup settlement is now less relevant given that the Supreme Court ruling reduces the routes for future litigation, the analysts say.
Bayer's stock surges 24% as SCOTUS wipes out 65,000 Roundup cancer lawsuits — and consumer protections with them
The ruling could save Bayer billions by derailing thousands of cancer claims — and may have implications far beyond Roundup for the products Americans use every day.
Millions use Roundup. The Supreme Court just made a major decision about it
The high court ruled that federal labeling rules shield Roundup from many state-law failure-to-warn claims.